From the impact of Obamacare to cutting edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health-care, and their implications for long-term investors. In this edition, the team talks about a potentially landmark Supreme Court ruling, the impact of President Barack Obama's budget on health care stocks, the next wave of innovation for the pharma industry, and why investors need to pay attention to a small research company from upstate New York.

In the segment below, health-care analyst David Williamson sums up the highs and lows of this quarter's early earnings seasons releases. Should investors be confident or concerned regarding stocks they own that have yet to report? Watch and find out how changing industry dynamics could impact your holdings.

Max Macaluso, Ph.D. has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid

The Motley Fool recommends Johnson & Johnson and UnitedHealth Group. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.